Research
Hormonal
Semaglutide (2.4 mg/week) improves physical function and reduces body weight in patients with heart failure with preserved ejection fraction (HFpEF) and obesity.
If you have heart failure with preserved ejection fraction and obesity, semaglutide (2.4 mg weekly) can help you feel better, walk further, and lose weight. It is taken as a weekly injection, starting at a low dose to minimize side effects.
StrongSupportsVERY_HIGH confidence
Analysis of the dual primary endpoints showed a mean change in the KCCQ-CSS at week 52 of 13.7 points in the semaglutide group... and a significant reduction in body weight at week 52 of 9.8% in the semaglutide group
Why this rating
Based on a randomized, placebo-controlled trial (STEP-HFpEF DM) with clear statistical significance.
Source
CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes
Oliver Schnell et al. · Cardiovascular Diabetology · 2025
narrative_reviewCited 15×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →